1
|
Bristow RE, Duska LR, Lambrou NC, et al: A
model for predicting surgical outcome in patients with advanced
ovarian carcinoma using computed tomography. Cancer. 89:1532–1540.
2000. View Article : Google Scholar : PubMed/NCBI
|
2
|
Parazzini F, Valsecchi G, Bolis G, et al:
Pelvic and paraortic lymph nodal status in advanced ovarian cancer
and survival. Gynecol Oncol. 74:7–11. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Pereira A, Magrina JF, Rey V, Cortes M and
Magtibay PM: Pelvic and aortic lymph node metastasis in epithelial
ovarian cancer. Gynecol Oncol. 105:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Du Bois A and Pfisterer J: Future options
for first-line therapy of advanced ovarian cancer. Int J Gynecol
Cancer. 15(Suppl 1): 42–50. 2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Winter WE III, Maxwell GL, Tian C, et al:
Prognostic factors for stage III epithelial ovarian cancer: a
Gynecologic Oncology Group Study. J Clin Oncol. 25:3621–3627. 2007.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Onda T: Neoadjuvant chemotherapy for
ovarian cancer. Gan To Kagaku Ryoho. 39:882–886. 2012.PubMed/NCBI
|
7
|
Muggia FM, Braly PS, Brady MF, et al:
Phase III randomized study of cisplatin versus paclitaxel versus
cisplatin and paclitaxel in patients with suboptimal stage III or
IV ovarian cancer: a gynecologic oncology group study. J Clin
Oncol. 18:106–115. 2000.PubMed/NCBI
|
8
|
Mouratidou D, Gennatas C, Michalaki V, et
al: A phase III randomized study comparing paclitaxel and cisplatin
versus cyclophosphamide and cisplatin in patients with advanced
ovarian cancer. Anticancer Res. 27:681–685. 2007.PubMed/NCBI
|
9
|
Markman M, Bundy BN, Alberts DS, et al:
Phase III trial of standard-dose intravenous cisplatin plus
paclitaxel versus moderately high-dose carboplatin followed by
intravenous paclitaxel and intraperitoneal cisplatin in
small-volume stage III ovarian carcinoma: an intergroup study of
the Gynecologic Oncology Group, Southwestern Oncology Group, and
Eastern Cooperative Oncology Group. J Clin Oncol. 4:1001–1007.
2001.
|
10
|
Kumar A, Gilks CB, Mar C, Santos J and
Tinker AV: Patterns of spread of clear cell ovarian cancer: Case
report and case series. Gynecol Oncol Rep. 6:25–27. 2013.
View Article : Google Scholar
|
11
|
Petit T, Velten M, d’Hombres A, et al:
Long-term survival of 106 stage III ovarian cancer patients with
minimal residual disease after second-look laparotomy and
consolidation radiotherapy. Gynecologic Oncology. 104:104–108.
2007. View Article : Google Scholar
|
12
|
Marsden DE, Friedlander M and Hacker NF:
Current management of epithelial ovarian carcinoma: a review. Semin
Surg Oncol. 19:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
|
13
|
Risum S, Høgdall C, Loft A, et al: The
diagnostic value of PET/CT for primary ovarian cancer - a
prospective study. Gynecol Oncol. 105:145–149. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
FIGO-International Federation of
Gynaecologists and Obstetricians Cancer Committee. Annual Report on
the Results of Treatment in Gynaecological Cancer. FIGO; Stockholm:
1979
|
15
|
Ozols RF, Bundy BN, Greer BE, et al:
Gynecologic Oncology Group: Phase III trial of carboplatin and
paclitaxel compared with cisplatin and paclitaxel in patients with
optimally resected stage III ovarian cancer: a Gynecologic Oncology
Group study. J Clin Oncol. 21:3194–3200. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bristow RE, Tomacruz RS, Armstrong DK, et
al: Survival effect of maximal cytoreductive surgery for advanced
ovarian carcinoma during the platinum era: a meta-analysis. J Clin
Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
17
|
Gadducci A, Cosio S, Conte PF and
Genazzani AR: Consolidation and maintenance treatments for patients
with advanced epithelial ovarian cancer in complete response after
first-line chemotherapy: a review of the literature. Critl Rev
Oncol Hematol. 55:153–166. 2005. View Article : Google Scholar
|
18
|
Morrison J, Haldar K, Kehoe S and Lawrie
TA: Chemotherapy versus surgery for initial treatment in advanced
ovarian epithelial cancer. Cochrane Database Syst Rev.
8:CD0053432012.PubMed/NCBI
|
19
|
Onda T and Yoshikawa H: Neoadjuvant
chemotherapy for advanced ovarian cancer: overview of outcomes and
unanswered questions. Expert Rev Anticancer Ther. 11:1053–1067.
2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Lambert HE, Gregory WM, Nelstrop AE and
Rustin GJ: Long-term survival in 463 women treated with platinum
analogs for advanced epithelial carcinoma of the ovary: Life
expectancy compared to women of an age-matched normal population.
Int J Gynecol Cancer. 14:772–778. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Rochet N, Sterzing F, Jensen AD, Dinkel J,
Herfarth KK, Schubert K, et al: Intensity-modulated whole abdominal
radiotherapy after surgery and carboplatin/taxane chemotherapy for
advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol
Phys. 76:1382–1389. 2010. View Article : Google Scholar
|